The invention relates to pharmaceutical compositions for the treatment or prevention of lesions of gastrointestinal mucous membranes and having secretion inhibiting, cytoprotective activities. The compositions contain in a biologically effective quantity a triazole-group-substituted quinoline derivative of general formula (I) R.sup.1 stands for a 1-triazolyl-group in position 2 or 4 or a 3-triazolyl-thio or a 5-/C.sub.1-4 -alkyl/-3-triazolyl-thio-group, R.sup.2 stands for a hydrogen atom in position 3 or optionally in position 2, or for a C.sub.1-4 -alkyl-group, R.sup.3 stands for a hydrogen atom or for a C.sub.1-4 -alkyl-group, X stands for a hydrogen or halogen-atom or for a C.sub.1-4 -alkyl-group or its salts. The invention includes processes for the preparation of the above compositions, and methods for treatment of patients in need of such treatment by administering the substance or the composition. The prefered substance of formula (IV) is also subject of the invention.
本发明涉及用于治疗或预防胃肠道黏膜损伤并具有分泌抑制和细胞保护活性的药物组合物。该组合物以
生物学有效的量含有一种三唑基取代的
喹啉衍
生物,其通式为(I)。其中,R.sup.1代表位于2或4位置的1-三唑基基团或3-三唑基
硫基或5-/C.sub.1-4-烷基/-3-三唑基
硫基基团;R.sup.2代表位于3或可选位于2位置的氢原子或C.sub.1-4-烷基基团;R.sup.3代表氢原子或C.sub.1-4-烷基基团;X代表氢原子或卤原子或C.sub.1-4-烷基基团或其盐。本发明还包括制备上述组合物的方法,以及通过给予该物质或组合物治疗需要此类治疗的患者的方法。式(IV)的优选物质也是本发明的对象。